AXSM (Axsome Therapeutics, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by AXSM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2026-07-01 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2026-06-11 | ROGER JEFFS | Director | Sell | — | — |
| 2026-06-10 | Susan Mahony | Director | MIXED | — | — |
| 2026-06-10 | Mark Coleman | Director | MIXED | — | — |
| 2026-06-10 | Mark E Saad | Director | M | — | — |
| 2026-06-10 | ROGER JEFFS | Director | M | — | — |
| 2026-06-09 | ROGER JEFFS | Director | A | — | — |
| 2026-06-09 | Susan Mahony | Director | A | — | — |
| 2026-06-09 | Mark E Saad | Director | A | — | — |
| 2026-06-09 | Mark Coleman | Director | A | — | — |
| 2026-06-09 | Nick Pizzie | Chief Financial Officer | MIXED | — | — |
| 2026-06-09 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2026-06-02 | Mark Coleman | Director | Sell | — | — |
| 2026-05-05 | Mark L. Jacobson | Chief Operating Officer | MIXED | — | — |
| 2026-04-23 | Ari Maizel | Chief Commercial Officer | A | — | — |
| 2026-04-23 | Hunter R. Murdock | General Counsel | A | — | — |
| 2026-04-23 | Mark L. Jacobson | Chief Operating Officer | A | — | — |
| 2026-04-23 | HERRIOT TABUTEAU | Chief Executive Officer | A | — | — |
| 2026-04-23 | Ari Maizel | Chief Commercial Officer | MIXED | — | — |
| 2026-04-23 | Nick Pizzie | Chief Financial Officer | A | — | — |
| 2026-02-27 | Nick Pizzie | Chief Financial Officer | A | — | — |
| 2026-02-27 | Mark L. Jacobson | Chief Operating Officer | A | — | — |
| 2026-02-27 | Ari Maizel | Chief Commercial Officer | A | — | — |
| 2026-02-27 | Hunter R. Murdock | General Counsel | A | — | — |
| 2026-02-27 | Mark Coleman | Director | Sell | — | — |
| 2026-02-27 | Mark L. Jacobson | Chief Operating Officer | MIXED | — | — |
| 2026-02-27 | HERRIOT TABUTEAU | Chief Executive Officer | A | — | — |
| 2026-02-25 | Mark Coleman | Director | M | — | — |
| 2026-02-23 | Mark Coleman | Director | M | — | — |
| 2026-02-10 | Mark Coleman | Director | M | — | — |
| 2026-02-02 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2026-01-23 | Ari Maizel | Chief Commercial Officer | MIXED | — | — |
| 2026-01-23 | Nick Pizzie | Chief Financial Officer | MIXED | — | — |
| 2026-01-07 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2026-01-02 | Mark E Saad | Director | MIXED | — | — |
| 2025-12-04 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2025-11-05 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2025-10-08 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2025-09-22 | Mark L. Jacobson | Chief Operating Officer | MIXED | — | — |
| 2025-09-17 | Mark L. Jacobson | Chief Operating Officer | MIXED | — | — |
| 2025-09-16 | HERRIOT TABUTEAU | Chief Executive Officer | MIXED | — | — |
| 2025-09-09 | Mark Coleman | Director | Buy | — | — |
| 2025-09-05 | Mark E Saad | Director | MIXED | — | — |
| 2025-09-02 | ROGER JEFFS | Director | Sell | — | — |
| 2025-08-29 | ROGER JEFFS | Director | Sell | — | — |
| 2025-08-26 | ROGER JEFFS | Director | Sell | — | — |
| 2025-06-23 | Hunter R. Murdock | General Counsel | MIXED | — | — |
| 2025-06-18 | Hunter R. Murdock | General Counsel | MIXED | — | — |
| 2025-06-10 | Mark L. Jacobson | Chief Operating Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 7,351,729 | — |
| — | Director | 434,888 | — |
| — | Director | 105,565 | — |
| — | Chief Financial Officer | 76,355 | — |
| — | Director | 11,731 | — |
| — | Chief Medical Officer | 11,044 | — |
| — | General Counsel | 7,500 | — |
| — | Chief Commercial Officer | 7,500 | — |
| — | Vice President, Finance | 4,358 | — |
| — | Director | 829 | — |
| — | Chief Operating Officer | 233 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AXSM quote page; the site-wide leaderboard is on the insider transactions hub.